Press Resease

Radiopharmaceutical Market - Global Industry Analysis

Radiopharmaceutical Market - by Type (Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals), By Application (Cardiology, Neurology, Oncology, and Other Applications) - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2019 – 2026

Published Date: 10-Aug-2016 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-86 Status : Published

Global Radiopharmaceutical Market, which was estimated at 4.3 (USD Billion) in 2019 and is predicted to accrue earnings worth around 9 (USD Billion) by 2026, is set to record a CAGR of nearly 8% over 2019-2026

Description

The global Radiopharmaceutical market, which was estimated at 4.3 (USD Billion) in 2019 and is predicted to accrue earnings worth around 9 (USD Billion) by 2026, is set to record a CAGR of nearly 8% over 2019-2026. The report offers valuation and analysis of Radiopharmaceutical market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2013 to 2015 along with a forecast from 2019 to 2026 based on value (USD Billion).

Introduction

Radiopharmaceuticals are a cluster of pharma medicines comprising of radioactive isotopes and they emit radiations. They are utilized for therapeutic or diagnostic interventions. These products are likely to locate on specific tissues as a result of their bio-molecular characteristics. A large number of radiopharmaceuticals are utilized for internal treatment of inflammatory & malignant lesions in the field of nuclear medicine. Radiopharmaceuticals are used for effectively treating various kinds of cancers. With FDA approving many of the radiopharmaceutical agents the treatment potential of these products is gaining significance and recognition across the pharma & healthcare sectors.

Market Growth Drivers

Escalating application of radioisotopes in the healthcare sector and surge in the utilization of the radiopharmaceuticals for detecting & treating chronic ailments will steer the business growth over the years to come. In addition to this, technological breakthroughs witnessed across the healthcare industry will further prompt the expansion of radiopharmaceutical market in the years ahead. Apart from this, surge in the aging population and assessing of novel medicines along with disease indication mortality will steer the business landscape in the forthcoming timespan.

Furthermore, rise in the occurrence of cancer coupled with massive need for nuclear scans for exact diagnosis of chronic ailments are few of the major aspects likely to steer the expansion of the radiopharmaceutical industry over the forecast timespan. Additionally, cost benefits as compared to use of radioactive tracers & access of advanced diagnostic equipment like PET and SPECT are likely to play a major role in the growth of radiopharmaceutical industry over the forthcoming years.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Asia Pacific Market To Grow At Rapid Rate Over Forecast Timespan

The growth of the market in the region over the estimated timeline is due to increase in the presence of radiopharmaceutical firms in China, Russia, Singapore, and India. Apart from this, immense pool of aging population prone to chronic ailments including heart disorders and neurological ailments in the region will prompt the need of minimally invasive treatments and this will further drive the product penetration across medical sector in the sub-continent over the coming decade. Growing awareness about benefits offered by radiopharmaceuticals across the medical fraternity in the sub-continent will further boost the business landscape in the Asia Pacific zone over the forecast timespan.

Key players leveraging the market growth include Jubilant Pharma, Lantheus Medical Imaging, Inc., Mallinckrodt plc, Cardinal Health, Inc., GE Healthcare, Advanced Accelerator Applications S.A., Bracco Imaging S.p.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Bayer Healthcare, IBA Molecular Imaging, and Siemens Healthcare.

Radiopharmaceuticals Market: Type Segment Analysis

  • Diagnostic Radiopharmaceuticals
    • SPECT 
    • PET 
  • Therapeutic radiopharmaceuticals
    • Beta emitters
    • Alpha emitters
    • Brachytherapy isotopes

Radiopharmaceuticals Market: Application Segment Analysis

  • Cardiology
  • Neurology
  • Oncology
  • Other

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Radiopharmaceutical Market, 2019 - 2026, (USD Billion)
    • 2.2. Radiopharmaceutical : Market snapshot
  • Chapter 3. Radiopharmaceutical Market: Industry Analysis
    • 3.1. Radiopharmaceutical : Market dynamics
    • 3.2. Value Chain Analysis
    • 3.3. Market Drivers
      • 3.3.1. Growing demand for PET and SPECT radioisotopes
      • 3.3.2. Increasing incidences of cancer and heart diseases
    • 3.4. Restraints
      • 3.4.1. Stringent regulatory guidelines
      • 3.4.2. Shorter half-life of nuclear medicine
    • 3.5. Opportunity
      • 3.5.1. Advancing technologies and ongoing research
    • 3.6. Porter’s Five Forces Analysis
    • 3.7. Market Attractiveness Analysis
      • 3.7.1. Market attractiveness analysis by type segment
      • 3.7.2. Market attractiveness analysis by application segment
      • 3.7.3. Market attractiveness analysis by regional segment
  • Chapter 4. Global Radiopharmaceutical Market: Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global radiopharmaceutical market: company market share, 2019
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Product and Regional Expansion
    • 4.3. Price Trend Analysis
    • 4.4. Product Portfolio
    • 4.5. Patent Analysis 
      • 4.5.1. Patent Trend
      • 4.5.2. Patent Share by company
      • 4.5.3. By Region
  • Chapter 5. Global Radiopharmaceutical Market: Product Overview
    • 5.1. Global radiopharmaceutical market share, by type, 2019 - 2026
    • 5.2. Global diagnostic radiopharmaceutical market, 2019 - 2026 (USD Billion)
    • 5.3. Global therapeutic radiopharmaceutical market, 2019 - 2026 (USD Billion)
  • Chapter 6. Global Radiopharmaceutical Market: Application Overview
    • 6.1. Global radiopharmaceutical market share, by application, 2019 - 2026
    • 6.2. Global radiopharmaceutical market for cardiology, 2019 - 2026 (USD Billion)
    • 6.3. Global radiopharmaceutical market for neurology, 2019 - 2026 (USD Billion)
    • 6.4. Global radiopharmaceutical market for oncology, 2019 - 2026 (USD Billion)
    • 6.5. Global radiopharmaceutical market for other, 2019 - 2026 (USD Billion)
  • Chapter 7. Global Radiopharmaceutical Market: Regional Analysis
    • 7.1. Global radiopharmaceutical market: Regional overview
      • 7.1.1. Global radiopharmaceutical market share, by region, 2019 - 2026
    • 7.2. North America
      • 7.2.1. North America radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
      • 7.2.2. North America radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
        • 7.2.3.2. U.S. radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
      • 7.3.2. Europe radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
      • 7.3.3. UK
        • 7.3.3.1. UK radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
        • 7.3.3.2. UK radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
      • 7.3.4. France
        • 7.3.4.1. France radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
        • 7.3.4.2. France radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
      • 7.3.5. Germany
        • 7.3.5.1. Germany radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
        • 7.3.5.2. Germany radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia-Pacific radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
      • 7.4.2. Asia-Pacific radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
      • 7.4.3. China
        • 7.4.3.1. China radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
        • 7.4.3.2. China radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
      • 7.4.4. Japan
        • 7.4.4.1. Japan radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
        • 7.4.4.2. Japan radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
      • 7.4.5. India
        • 7.4.5.1. India radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
        • 7.4.5.2. India radiopharmaceutical market revenue, by technology, 2019 - 2026 (USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
      • 7.5.2. Latin America radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
        • 7.5.3.2. Brazil radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
    • 7.6. Middle East & Africa
      • 7.6.1. Middle East & Africa radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
      • 7.6.2. Middle East & Africa radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)
  • Chapter 8. Company Profiles
    • 8.1. Cardinal Health, Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. GE Healthcare
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. Bracco Imaging S.p.A
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Nordion, Inc.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
      • 8.5. Advanced Accelerator Applications S.A.
    • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Bayer Healthcare
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Lantheus Medical Imaging, Inc.
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
  • Chapter 9. Patents
    • 9.1. U.S. (US Patents)
    • 9.2. Europe (EP documents)
    • 9.3. Japan (Abstracts of Japan)
    • 9.4. Global (WIPO (PCT))

List of Figures

1. Global radiopharmaceutical  market segmentation by type, application, and geography
2. Global radiopharmaceutical  market, 2019 - 2026 (USD Billion)
3. Value chain analysis: Radiopharmaceutical  market
4. Porter’s five forces analysis: Radiopharmaceutical  market
5. Market attractiveness analysis by type segment
6. Market attractiveness analysis by application segment 
7. Market attractiveness analysis by regional segment 
8. Global Radiopharmaceutical  Market : Company Market Share, 2015 
9. Price Trend Analysis : Radiopharmaceutical  
10. Patent trend between 2011 -2016 
11. Patent Share by Company between 2011 - 2016 
12. Patent Share by Region between 2011 - 2016
13. Global radiopharmaceutical  market share, by type, 2019 - 2026
14. Global diagnostic radiopharmaceutical  market, 2019 - 2026 (USD Billion)
15. Global therapeutic radiopharmaceutical  market, 2019 - 2026 (USD Billion)
16. Global radiopharmaceutical  market share, by application, 2019 - 2026
17. Global radiopharmaceutical  market for cardiology, 2019 - 2026 (USD Billion)
18. Global radiopharmaceutical  market for oncology, 2019 - 2026 (USD Billion)
19. Global radiopharmaceutical  market for neurology, 2019 - 2026 (USD Billion)
20. Global radiopharmaceutical  market for others, 2019 - 2026 (USD Billion)
21. Global radiopharmaceutical  market share, by region, 2019 - 2026
22. North America radiopharmaceutical  market, 2019 - 2026, (USD Billion)
23. U.S. radiopharmaceutical  market, 2019 - 2026,  (USD Billion)
24. Europe radiopharmaceutical  market, 2019 - 2026, (USD Billion)
25. UK radiopharmaceutical  market, 2019 - 2026, (USD Billion)
26. France radiopharmaceutical  market, 2019 - 2026,  (USD Billion)
27. Germany radiopharmaceutical  market, 2019 - 2026, (USD Billion)
28. Asia Pacific radiopharmaceutical  market, 2019 - 2026, (USD Billion)
29. China radiopharmaceutical  market, 2019 - 2026,  (USD Billion)
30. Japan radiopharmaceutical  market, 2019 - 2026,  (USD Billion)
31. India radiopharmaceutical  market, 2019 - 2026, (USD Billion)
32. Latin America radiopharmaceutical  market, 2019 - 2026,  (USD Billion)
33. Brazil radiopharmaceutical  market, 2019 - 2026,  (USD Billion)
34. Middle East & Africa radiopharmaceutical  market, 2019 - 2026, (USD Billion)


List of Tables

1. Global radiopharmaceutical  market snapshot
2. Drivers for radiopharmaceutical  market: Impact analysis
3. Restraints of radiopharmaceutical  market: Impact analysis
4. North America radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
5. North America radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
6. U.S. radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
7. U.S. radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
8. Europe radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
9. Europe radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
10. UK radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
11. UK radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
12. France radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
13. France radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
14. Germany radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
15. Germany radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
16. Asia-Pacific radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
17. Asia-Pacific radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
18. China radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
19. China radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
20. Japan radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
21. Japan radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
22. India radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
23. India radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
24. Latin America radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
25. Latin America radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
26. Brazil radiopharmaceutical  market revenue, by type, 2019 - 2026 (USD Billion)
27. Brazil radiopharmaceutical  market revenue, by application, 2019 - 2026 (USD Billion)
28. Middle East & Africa radiopharmaceutical market revenue, by type, 2019 - 2026 (USD Billion)
29. Middle East & Africa radiopharmaceutical market revenue, by application, 2019 - 2026 (USD Billion)

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Radiopharmaceutical market. Zion Research has collected and analyzed key data belong to the global Radiopharmaceutical market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Radiopharmaceutical across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Radiopharmaceutical industry. Primary research makes up a major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Radiopharmaceutical market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Radiopharmaceuticals are therapeutic agents used to diagnose certain medical condition or treat certain diseases. Unlike other imaging techniques such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasound (US), nuclear medicine processes are capable of mapping metabolic activity and physiological function. Radiopharmaceutical procedure provides more precise information about the organ function or dysfunction. Nuclear medicine may be given to the patient in various different ways. They may be given by injection, given orally, or placed into the bladder.

 Radiopharmaceuticals are to be given only under the direct supervision of a doctor with specialized training in nuclear medicine. Radiopharmaceutical process is rigorously regulated by the European Medicines Agency (EMA) in Europe and Food and Drug Administration (FDA) in the U.S. General interval for approval of process is typically five to eight years, from the early discovery to the availability for the physicians.

Radiopharmaceutical market growth is triggered by growing demand for PET and SPECT radioisotopes. Single-photon emission computed tomography (SPECT) and Positron emission tomography (PET) are the nuclear medicine imaging techniques.  Other factors contributing to this growth include increasing incidences of cancer and heart diseases.. However, factors such as stringent regulatory guidelines, shorter half-life of nuclear medicine and competition from conventional diagnostic procedures can affect the growth of this market.

Radiopharmaceutical market is segmented on the basis of type, application and region. On the basis of type radiopharmaceutical market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals.  The diagnostics segment is classified into SPECT and PET. Diagnostic radiopharmaceuticals segment acquired largest market in 2015 owing to well established use of radio isotopes in diagnostic imaging. Cardiology and oncology are the core application areas of for diagnostic radiopharmaceutical.  The therapeutic radiopharmaceuticals segment is expected to show fastest growth in forecast period due to its advantages over traditional therapies and drugs. The therapeutics segment is further divided into beta emitters, alpha emitters, and brachytherapy isotopes.

Radiopharmaceutical application segment includes cardiology, neurology, oncology, and other. Cardiology application segment accounted for significant share of radiopharmaceutical market in 2015. Cancer is, therefore, emerging as a lucrative application area for radiopharmaceuticals industry.

Geographically, the global radiopharmaceutical market is segmented into North America, Europe, Latin America, Asia-Pacific, and Middle East and Africa. The radiopharmaceutical market was dominated by North America accounting for the largest share of the total market in 2015. In 2015, U.S. accounted for the major share of the North American radiopharmaceuticals market, followed by Canada. The key factors driving market growth in the U.S. include approval for new nuclear medicine by the FDA in this region. An alternative treatment for cancer and growing prevalence of thyroid cancer also boosts the global radiopharmaceutical market growth.

The Asia-Pacific radiopharmaceuticals market is expected to grow at the fastest rate during the forecast period owing to a rise in the demand for PET and SPECT devices coupled with rising patient awareness for cardiovascular diseases and oncology.

Some of the major players in the radiopharmaceuticals market include Cardinal Health, Inc., GE Healthcare, Bracco Imaging S.p.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Advanced Accelerator Applications S.A., Bayer Healthcare, Lantheus Medical Imaging, Inc., IBA Molecular Imaging, Mallinckrodt plc, Jubilant Pharma, and Siemens Healthcare.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Escalating application of radioisotopes in the healthcare sector and surge in the utilization of the radiopharmaceuticals for detecting & treating chronic ailments will steer the business growth over the years to come. In addition to this, technological breakthroughs witnessed across the healthcare industry will further prompt the expansion of radiopharmaceutical market in the years ahead. Apart from this, surge in the aging population and assessing of novel medicines along with disease indication mortality will steer the business landscape in the forthcoming timespan.

According to Zion market research report, The Global Radiopharmaceutical Market, which was estimated at 4.3 (USD Billion) in 2019 and is predicted to accrue earnings worth around 9 (USD Billion) by 2026, is set to record a CAGR of nearly 8% over 2019-2026

Asia Pacific is likely to make noteworthy contributions towards overall market revenue. The regional market growth over 2016-2021 can be credited to increase in the presence of radiopharmaceutical firms in China, Russia, Singapore, and India. Apart from this, immense pool of aging population prone to chronic ailments including heart disorders and neurological ailments in the region will prompt the need of minimally invasive treatments and this will further drive the product penetration across medical sector in the sub-continent over the coming decade. Growing awareness about benefits offered by radiopharmaceuticals across the medical fraternity in the sub-continent will further boost the business landscape in the Asia Pacific zone over the forecast timespan.

The key players profiled in the report include Jubilant Pharma, Lantheus Medical Imaging, Inc., Mallinckrodt plc, Cardinal Health, Inc., GE Healthcare, Advanced Accelerator Applications S.A., Bracco Imaging S.p.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Bayer Healthcare, IBA Molecular Imaging, and Siemens Healthcare.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed